Added value of digital PET/CT in (re)staging patients with pancreatic cancer - (Re)stadiering of digital PET in pancreatic cancer

Isala Klinieken0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•Histological or cytological confirmed malignant peri-ampullary tumour, resectable or borderline resectable, without evidence of distant metastases.
•Inclusion in the Preopanc-2 study and randomized for neo-adjuvant chemotherapy
•Written informed consent
•There is an additional inclusion criterion for the acquisition of the second FDG-PET/CT scan: only patients that are treated with at least 4 cycles, and a maximum of 8 cycles of neo-adjuvant chemotherapy will be referred for this FDG-PET/CT scan.

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•Age < 18 years
•Incapacitated adults
•Prisoners
•Pregnancy
•Unable to undergo a FDG-PET/CT scan
•Metastatic or locally advanced (i.e. unresectable) pancreatic cancer
•Ampullary or distal bile duct cancer.
•Prior radiotherapy, chemotherapy, or resection for pancreatic cancer.
•Previous malignancy (excluding non-melanoma skin cancer), unless no evidence of disease and diagnosed more than 2 years before diagnosis of pancreatic cancer.
•Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.

发起方

Isala Klinieken